Lloyd E Damon

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma
    L Damon
    Division of Hematology Oncology, University of California, San Francisco, CA 94143 0324, USA
    Bone Marrow Transplant 42:649-57. 2008
  2. ncbi Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
    Lloyd E Damon
    University of California Medical Center, The Helen Diller Comprehensive Cancer Center, 400 Parnassus Ave, San Francisco, CA 94143 0324, USA
    J Clin Oncol 27:6101-8. 2009
  3. ncbi Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim
    Lloyd Damon
    University of California, San Francisco, San Francisco, California 94143 0324, USA
    Biol Blood Marrow Transplant 12:316-24. 2006
  4. ncbi Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule
    Lloyd E Damon
    Division of Hematology Oncology, University of California, San Francisco, 400 Parnassus Avenue, Box 0324, San Francisco, CA 94143, USA
    Cancer Chemother Pharmacol 53:468-74. 2004
  5. ncbi Mobilization of hematopoietic stem cells into the peripheral blood
    Lloyd E Damon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143 0324, USA
    Expert Rev Hematol 2:717-33. 2009
  6. ncbi High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer
    Uzair B Chaudhary
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Am J Clin Oncol 28:130-7. 2005
  7. ncbi Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma
    Sara Gonias
    Department of Pediatrics, University of California, San Francisco, 350 Parnassus Ave, Suite 710, San Francisco, CA 94117, USA
    J Clin Oncol 27:4162-8. 2009
  8. ncbi Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI
    Matthew J Wieduwilt
    Division of Hematology Oncology, University of California San Francisco, Box 1270, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Clin Cancer Res 18:1146-55. 2012
  9. ncbi Pandemic (H1N1) 2009 infection in patients with hematologic malignancy
    Catherine Liu
    University of California, San Francisco, Division of Infectious Diseases, California 94143 0654, USA
    Emerg Infect Dis 16:1910-7. 2010
  10. ncbi Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia
    Charles Linker
    Bone Marrow Transplant Program, Medical Center, University of California San Francisco, 400 Parnassus Avenue, Rm A502, San Francisco, CA 94143 0324, USA
    J Clin Oncol 20:2464-71. 2002

Collaborators

Detail Information

Publications17

  1. ncbi Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma
    L Damon
    Division of Hematology Oncology, University of California, San Francisco, CA 94143 0324, USA
    Bone Marrow Transplant 42:649-57. 2008
    ..The equalization of EFS and superiority of OS in patients intensely mobilized to those nonintensely mobilized suggests that a treatment strategy using intensive chemotherapy for mobilization may be improving NHL outcomes after ASCT...
  2. ncbi Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
    Lloyd E Damon
    University of California Medical Center, The Helen Diller Comprehensive Cancer Center, 400 Parnassus Ave, San Francisco, CA 94143 0324, USA
    J Clin Oncol 27:6101-8. 2009
    ..The incorporation of rituximab with aggressive chemotherapy and ASCT may be responsible for the encouraging outcomes demonstrated in this study, which produced results comparable to similar treatment regimens...
  3. ncbi Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim
    Lloyd Damon
    University of California, San Francisco, San Francisco, California 94143 0324, USA
    Biol Blood Marrow Transplant 12:316-24. 2006
    ....
  4. ncbi Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule
    Lloyd E Damon
    Division of Hematology Oncology, University of California, San Francisco, 400 Parnassus Avenue, Box 0324, San Francisco, CA 94143, USA
    Cancer Chemother Pharmacol 53:468-74. 2004
    ..The differences in toxicity of etoposide following continuous or bolus infusion are unknown...
  5. ncbi Mobilization of hematopoietic stem cells into the peripheral blood
    Lloyd E Damon
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143 0324, USA
    Expert Rev Hematol 2:717-33. 2009
    ..Patients failing to mobilize adequate hematopoietic stem cells with myeloid growth factors can often be successfully mobilized with chemotherapy plus myeloid growth factors or with plerixafor and granulocyte colony-stimulating factor...
  6. ncbi High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer
    Uzair B Chaudhary
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Am J Clin Oncol 28:130-7. 2005
    ..A significant correlation was seen between intended carboplatin dose and actual AUC. TVCa high-dose chemotherapy is active and well tolerated in patients with relapsed or refractory germ cell cancer...
  7. ncbi Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma
    Sara Gonias
    Department of Pediatrics, University of California, San Francisco, 350 Parnassus Ave, Suite 710, San Francisco, CA 94117, USA
    J Clin Oncol 27:4162-8. 2009
    ..To evaluate the safety and efficacy of high-dose [(131)I]metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL)...
  8. ncbi Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI
    Matthew J Wieduwilt
    Division of Hematology Oncology, University of California San Francisco, Box 1270, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Clin Cancer Res 18:1146-55. 2012
    ..In addition, we evaluated the prognostic value of the minimum apparent diffusion coefficient (ADC(min)) derived from diffusion-weighted MRI (DW-MRI) in patients treated with this regimen...
  9. ncbi Pandemic (H1N1) 2009 infection in patients with hematologic malignancy
    Catherine Liu
    University of California, San Francisco, Division of Infectious Diseases, California 94143 0654, USA
    Emerg Infect Dis 16:1910-7. 2010
    ..Rigorous infection control, improved techniques for diagnosing respiratory disease, and early antiviral therapy can prevent nosocomial transmission and optimize patient care...
  10. ncbi Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia
    Charles Linker
    Bone Marrow Transplant Program, Medical Center, University of California San Francisco, 400 Parnassus Avenue, Rm A502, San Francisco, CA 94143 0324, USA
    J Clin Oncol 20:2464-71. 2002
    ..To assess the efficacy and toxicity of a new treatment program of intensified and shortened cyclical chemotherapy (protocol 8707) in adults with acute lymphoblastic leukemia (ALL)...
  11. ncbi Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma
    James L Rubenstein
    Division of Hematology Oncology, and the Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 25:1350-6. 2007
    ..We therefore conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL)...
  12. ncbi Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)
    Paul A Fitzgerald
    Department of Medicine, UCSF Comprehensive Cancer Center, Box 1222, University of California, San Francisco, San Francisco, CA 94143 1222, USA
    Ann N Y Acad Sci 1073:465-90. 2006
    ..For patients with metastatic PHEO or PGL, who have good *I-MIBG uptake on diagnostic scanning, high-dose 131I-MIBG therapy was effective in producing a sustained CR, PR, or SD in 67% of patients, with tolerable toxicity...
  13. ncbi Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
    James L Rubenstein
    Division of Hematology Oncology, Comprehensive Cancer Center, Cancer Research Institute, Department of Neurosurgery, UCSF, San Francisco, CA 94143, USA
    Blood 101:466-8. 2003
    ..96 hours. A phase 1 study to investigate the safety and pharmacokinetics of intrathecal rituximab in patients with recurrent lymphomatous meningitis will be implemented based on these findings...
  14. ncbi Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
    James L Rubenstein
    Division of Hematology Oncology and Helen Diller Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
    Blood 121:745-51. 2013
    ..KEY POINTS: Phase I study showed that intraventricular rituximab plus methotrexate is feasible and active in the treatment of refractory CNS lymphoma...
  15. ncbi High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia
    Nathan Gunn
    Department of Medicine, Division of Hematology/Oncology, University of California-San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
    Biol Blood Marrow Transplant 9:643-8. 2003
    ..0 versus 9.8 units; P =.01). Our findings suggest that CD34+ cell doses >10 x 10(6)/kg CD34+ result in faster engraftment and fewer red blood cell and platelet transfusions...
  16. ncbi Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia
    Garth Beinart
    Department of Hematology Oncology, University of California San Francisco, San Francisco, California, USA
    Am J Hematol 77:331-5. 2004
    ..This results in a specificity of 90% and a relative risk of 10 (P = 0.014). Therefore, a fibrinogen <50 mg/dL may serve as a marker for a hypercoagulable state in ALL patients receiving L-asparaginase...
  17. ncbi Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008